BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Friday, February 13, 2026
See today's BioWorld
Home
» Reading the Tea Leaves for Interferon's Future in HCV
To read the full story,
subscribe
or
sign in
.
Reading the Tea Leaves for Interferon's Future in HCV
Oct. 11, 2010
By
Trista Morrison
Last week's complete response letter for Human Genome Sciences Inc. and Novartis AG's Zalbin (albinterferon alfa-2b) came as no surprise given the hepatitis C drug's history.
BioWorld
